Use of cholinesterase inhibitors in dementia
نویسندگان
چکیده
منابع مشابه
Use of cholinesterase inhibitors in dementia
Alzheimer’s disease is the most common cause of dementia in older people, with about half a million people affected in the UK. Its effects are devastating and far-reaching for sufferers, their carers and society in general – the Audit Commission estimated the annual cost of dementia care for 1998–1999 at £6.1 billion (Audit Commission, 2000). There is no cure and it is terminal within 3 to 7 ye...
متن کاملCholinesterase inhibitors in the treatment of dementia.
Dementia associated with probable Alzheimer's disease (AD) is one of the most common types of dementia. Patients with AD often have cholinergic deficits in association with the disease. The cholinesterase inhibitors donepezil hydrochloride, galantamine hydrobromide, and rivastigmine tartrate are the current mainstays of symptomatic treatment for patients with AD. In clinical trials for all thre...
متن کاملTreatment of dementia in parkinsonian syndromes with cholinesterase inhibitors.
In Parkinsonian syndromes behavioural symptoms and dementia can be even more debilitating than motor symptoms and are an important predictor for nursing home placement and mortality. Neuropathologically, dementia seems to be primarily related to cortical changes rather than to subcortical alterations. Concerning neurotransmitter systems, the cholinergic system has been proposed to play a key ro...
متن کاملA review of studies describing the use of acetyl cholinesterase inhibitors in Parkinson's disease dementia.
OBJECTIVE To review the literature relating to the use of acetyl cholinesterase inhibitors in Parkinson's disease dementia (PDD). METHOD MEDLINE (1966--December 2004), PsychINFO (1972--December 2004), EMBASE (1980--December 2004), CINHAL (1982--December 2004), and the Cochrane Collaboration were searched in December 2004. RESULTS Three controlled trials and seven open studies were identifie...
متن کاملCholinesterase inhibitors in dementia: yes, no, or maybe?
Often it is not for the benefit of patients, when a clinical issue is debated in public domain. Currently, patients with dementia who are considered for treatment with one of the cholinesterase inhibitors are in danger of being crushed between clinical opinion leaders, national guidelines, pharmaceutical companies and politicians. After a review of the cost effectiveness of cholinesterase inhib...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Advances in Psychiatric Treatment
سال: 2002
ISSN: 1355-5146,1472-1481
DOI: 10.1192/apt.8.2.89